Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-102 in Allergic Conjunctivitis
NCT03012165Phase 2Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Dec 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of reproxalap in allergic conjunctivitis (AC), sponsored by Aldeyra Therapeutics. Started Dec 2016; status: completed.
02
Drugs
reproxalap
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT03012165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012165.